{"analyses":[{"ciLowerLimit":"0.577","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.286","estimateComment":"Hazard Ratio (HR) was based on an unstratified Cox proportional hazard regression model with treatment as a factor.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.464","pValueComment":"P-value is from an unstratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.861","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.57","upperLimit":"27.73","value":"19.0"},{"groupId":"OG001","lowerLimit":"18.53","upperLimit":"30.88","value":"21.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death at the time of the analysis were censored at the date the participant was last known to be alive. The Kaplan Meier estimates was used for the analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"ITT Population was defined as all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From date of randomization until death (up to 3 years and 5 months)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}